In six patients with extrinsic bronchial asthma the inhalation of prostaglandin (PG) F,a in a small dosage produced significant bronchoconstriction, whereas PGE, produced bronchodilatation. In these patients cholinergic blockade with atropine partially inhibited the PGF2a-induced bronchoconstriction, but the a-receptor-blocking drug thymoxamine and sodium cromoglycate did not.
Introduction
Human lung contains prostaglandins (PG) of both the E and F series, E, and F2a being the most abundant.' 2 PGF2,a, a potent bronchoconstrictor to which patients with bronchial asthma are highly sensitive,'' is released from mammalian lungs during anaphylactic reactions6 and by various chemical and mechanical stimuli.7 Recently, a considerable increase in plasma levels of PGF2 a metabolites in asthmatic patients after allergen challenge was reported.8 Based on these observations it was postulated that locally formed PGF2a may play an important part in the pathogenesis of bronchial asthma. PGE2, on the other hand, causes bronchodilatation in man.3 5 PGE, activates adenyl cyclase, now identified with ,B-receptor function, [9] [10] [11] and its bronchodilator effect is mediated by an increase in cyclic adenosine monophosphate (cyclic AMP).
Conversely, PGF2a has been reported to activate guanyl cyclase and lead to the formation of cyclic guanosine monophosphate (cyclic GMP).12 Guanyl inhibited PGF2a-induced bronchoconstriction in these patients. In contrast, sodium cromoglycate and thymoxamine failed to change the mean FEV1 and SGaw, and neither of these drugs had any effect on the PGF2a-induced bronchoconstriction. PGF2a in some patients caused symptoms of upper airway irritation-cough, substernal tightness, and increased mucous secretion-similar to those experienced after methacholine inhalation.
PGF2a is released from guinea-pig and rat lungs during anaphylactic reactions6 and by various chemical and mechanical stimuli.7 The release of PGF2a during type I allergic reactions and the observation of increased sensitivity of asthmatic patients to inhaled PGF2a led Mathe et al.5 to postulate that endogenous, locally formed PGF2a may play an important part in the pathogenesis of bronchial asthma. This view was supported by a report of about an eightfold increase in plasma levels of 15-keto-13,14-dihydroprostaglandin F2a, the main metabolite of PGF2 a, in asthmatic patients after allergen challenge.8 Local PGF2a release in the lung has been suggested as the mechanism of exercise-induced asthma," 9 and the demonstration of this release in guinea-pig lungs in response to minor mechanical stimuli supports this view. The results of the present investigation, however, suggest that sodium cromoglycate does not inhibit PGF2 a-induced bronchoconstriction in asthmatic patients.
This effect of sodium cromoglycate on PGF2oa-induced bronchoconstriction together with the observations of its inhibitory effect in allergen-provoked20 and exercise-provoked2l asthma suggest that the release of prostaglandins locally in the lung may not be the primary factor in the pathogenesis of asthma. In addition, indomethacin administration, which considerably reduces the total body production of PGF2a, does not completely inhibit allergen-provoked asthma in man or anaphylactic reactions in guinea-pigs. 22 The studies on cyclic nucleotide systems suggest that the effects of PGE2 are mediated through ,-adrenergic receptors, whereas PGF2a may activate cholinergic receptors. The partial inhibition of PGF2ax-induced bronchoconstriction by atropine as reported here is consistent with this hypothesis. a-Blockade with thymoxamine failed to inhibit the PGF2 a-induced bronchoconstriction in these patients with asthma, which suggests that PGF2ac does not stimulate a-receptors in the lung. In man, cholinergic or vagal stimulation causes bronchoconstriction, which is grossly exaggerated in asthma.23 The evidence so far suggests that PGF2 a together with other chemical mediators such as histamine, bradykinin, serotonin, and SRS-A are released during the type I allergic reaction. PGF2ac is a potent bronchoconstrictor to which asthmatic patients are highly sensitive, and it may act by stimulating cholinergic receptors. Airways hyperreactivity to chemical mediators released in the type I allergic reaction is now well recognized in patients with asthma. Though Szentivayni24 suggested that this hyperreactivity in asthma may result from an imbalance between the a-and 3-adrenergic receptors in the lung, the evidence to support this theory is not conclusive.25 It would be wrong to consider PGF2ac as the main factor in the pathogenesis of asthma until we further clarify the cause of airways hyperreactivity, which appears to be the primary defect in asthmatic patients.
